MET and neoplasm: Previous studies involving patients with MET-amplified advanced NSCLC have reported greater efficacy in tumors with a high gene copy number than in those with a low gene copy number, and clinical trials of capmatinib have revealed that a gene copy number (GCN) ≥ 6 is associated with satisfactory anti-tumor activity (48, 49).